What is Conexeu?
Conexeu is a regenerative medicine company focused on developing CXU, a novel collagen-based extracellular matrix scaffold. This medical device candidate is engineered to support and promote tissue regeneration across a variety of applications. The company's preclinical platform targets critical areas such as wound care, aesthetics, oral health, and animal health, with potential applications extending to 3D bioprinting through its structural tissue restoration capabilities.
How much funding has Conexeu raised?
Conexeu has raised a total of $4.1M across 6 funding rounds:
Private Equity
$1.3M
Multiple Rounds
$2.7M
Private Equity (2025): $1.3M, investors not publicly disclosed
Private Equity (2026): $810K, investors not publicly disclosed
Private Equity (2026): $45K, investors not publicly disclosed
Private Equity (2026): $1.8M, investors not publicly disclosed
Private Equity (2026): $45K, investors not publicly disclosed
Private Equity (2026): $23K, investors not publicly disclosed
What's next for Conexeu?
With the infusion of major enterprise-level funding and recent substantial expansion capital, Conexeu is strategically positioned for significant advancement. The company is expected to leverage this investment to scale its operations, advance its CXU platform through clinical trials, and potentially expand its market reach into new therapeutic areas. This financing signals strong investor confidence in Conexeu's potential to disrupt the regenerative medicine landscape and address unmet needs in tissue repair and restoration.
See full Conexeu company page
